Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis

Aug 12, 2026 Press Releases

PDF Version NAPLES, Fla., August 12, 2026 — Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has...

Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis

Jun 4, 2026 Press Releases

PDF Version NAPLES, Fla., June 4, 2026— Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has...

Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL amyloidosis

Dec 7, 2025 Posters & Publications

Click Here to View...

Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 4, 2025 Press Releases

PDF Version Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented at ASH. The presentation includes data on AL patients in hematological remission who...

Attralus Therapeutic AT-02 Receives Orphan Drug Designation from the U.S. FDA for the Treatment of ATTR Amyloidosis

Nov 12, 2024 Press Releases

PDF Version Naples, FL – November 12, 2024 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug...